Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RO6924963
- Development stage
- Phase 1
- Lead developer
- Roche
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
RO6924963 is a radiolabeled small molecule positron emission tomography (PET) imaging agent developed by Roche for the in vivo visualization of tau protein aggregates in the brain. Labeled with carbon-11 ([11C]), it is designed to bind selectively and with high affinity to neurofibrillary tangles composed of aggregated tau protein—a hallmark pathology of Alzheimer’s disease (AD). Preclinical studies demonstrated that [11C]RO6924963 exhibits good brain entry, rapid washout, favorable metabolism patterns, and high specificity for tau aggregates over amyloid-β plaques or other central nervous system targets. The compound was evaluated alongside other candidate tracers as part of a program to develop sensitive and selective PET tracers for detecting longitudinal changes in tau load during AD progression or therapeutic intervention trials[2][6][8].
- Other names
- [11C]RO-963[11C]RO6924963
02
Targets
MAPT (Microtubule-associated protein tau)
Beyond the preview
Go deeper on RO6924963.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RO6924963.